A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Nivolumab (Primary) ; Ulocuplumab (Primary)
  • Indications Pancreatic cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CXCessoR4
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 09 Mar 2017 Status changed from recruiting to discontinued because of lack of efficacy in the short term acute phase.
    • 17 Jul 2015 Planned number of patients changed from 189 to 195 as reported by ClinicalTrials.gov.
    • 17 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top